Vasa Therapeutics

Vasa Therapeutics is a private, preclinical-to-clinical stage biotech developing transformative small molecule therapies for diseases of cardiovascular aging and related disorders. Its lead asset, VS-041, is a narrow-spectrum MMP-2/9 inhibitor with FDA Fast Track designation currently in a Phase 1 Proof-of-Mechanism (PoM) study for Heart Failure with Preserved Ejection Fraction (HFpEF). The company leverages a founder-led team with a strong drug development track record and is backed by seed investors and non-dilutive EU grant funding, positioning it to advance a pipeline targeting significant unmet needs in heart failure, peripheral artery disease, and sarcopenia.

An integrated discovery and development philosophy focused on aligning validated disease biology (right mechanism) with precise medicinal chemistry (right chemistry), leveraging decades of team experience in drug discovery and clinical translation.

In HFpEF, Vasa competes with large pharma (e.g., Bayer, Novo Nordisk) and biotechs exploring diverse mechanisms like SGLT2 inhibitors, GLP-1 agonists, and other anti-fibrotics. In sarcopenia and PAD, the competitive field includes companies developing myostatin inhibitors, SARMs, and other anabolic agents. Vasa's differentiation lies in its narrow-spectrum MMP inhibition for fibrosis and its multi-indication apelin platform.